semaglutide and eye issues How Does Affect Health? TGA issues warning over GLP-1-based

Consume 30 to 60 minutes prior to training

Pushing the dose higher when a patient is already losing consistently doesnt accelerate results

CrossRef Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma Zizhong Yang, Lupeng Qiu, Guhe Jia, Zhuoya Sun, Yixin Gong, Yin Chen, Yu Wang, Lai Song, Xiao Zhao, Shunchang Jiao BMC Cancer .2025;[Epub] CrossRef Identification and validation of icaritin-associated prognostic genes in hepatocellular carcinoma through network pharmacology, bioinformatics analysis, and cellular experiments Yaru Shi, Yanan Bai, Jianglan Wu, Yunfeng Yu, Xinyu Yang, Haobo Yang, Weixiong Jian, Jun Qing Frontiers in Immunology .2025;[Epub] CrossRef Enhancing cancer risk awareness and screening management through artificial intelligence: a narrative review Jiaxuan Wu, Xiaolong Tang, Qian Zheng, Xinhang Gu, Li Ma, Jinghong Xian, Hui Mao, Jiadi Gan, Guiyi Ji Frontiers in Oncology .2025;[Epub] CrossRef miR-122-5p Regulates Ferroptosis through Targeting the Glutamine Transporter SLC1A5 in Hepatocellular Carcinoma Mingxuan Lei, Jiayin Xu, Xiaoying Hu, Lin Feng, Baoping Luo BIOCELL .2025

As agents such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) continue to deliver robust A1C reduction and double-digit weight loss, clinicians must balance metabolic gains with careful risk assessment